Pfizer – Research in Ulcerative Colitis RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Monday 29th, July 2024
External Deadline: Monday 5th, August 2024
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: June 14, 2024
Geographic Scope: Germany, Austria, Finland, Denmark, Norway, Netherlands, France, Italy, Spain, Switzerland, Belgium, Czech Republic, Canada, Australia, and United Kingdom
Clinical Area: Ulcerative Colitis
Link to full RFP: Research in Ulcerative Colitis (UC) 2024
Application Due Date: August 5, 2024
Specific Area of Interest: The intent of this Request for Proposal (RFP) is to support research to identify and address data gaps and advances understanding the role of etrasimod and tofacitinib in UC treatment landscape. More specifically:
- – Exploration, in a Real-World setting, for optimal ultrasonographic markers to assess and potentially predict response to treatment with Etrasimod
- – Evaluation of UC symptoms and disease domains including Extraintestinal Manifestations, in patients treated with Etrasimod or Tofacitinib in a Real-World setting
- – Evaluation of Etrasimod effectiveness, in a Real-World setting, in specific subgroups of special interest such as proctitis, adolescent
– Evaluation of advanced therapy sequencing strategy in Moderate to Severe UC including Etrasimod and/or Tofacitinib, in a Real-World setting - Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).